Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia

Table 3 Logistic regression analysis showing odds ratio for factors associated with the risk of immunologic and virologic failures of the HIV patients with no TB (HIV + TB-) at six months of ART

	Risk of immunologic failure (an increase of CD4+ < 50 cells/μl) at 6 months (n = 56)			Risk of virologic failure (HIV RNA > 5000 cells/μl) at 6 months (n = 69)
	OR	95% CI	P value	OR	95% CI	P value
Sex
Male	1			1
Female	0.62	1.0-1.9	0.40	0.51	0.12-2.1	0.93
Age (years)
36-60	1			1
16–35	0.65	0.21-2.0	0.44	0.41	0.10- 1.7	0.21
BMI
<18.50	1			1
> = 18.50	0.90	0.25- 3.29	0.87	3.75	1.0-14.4	0.05
Hgb
< 12	1			1
> = 12	0.38	0.08-1.7	0.21	0.19	0.02-1.6	0.13
CD4+ count/μl
> = 100	1			1
<100	5.6	1.6-20.1	0.008	2.3	0.45- 11.2	0.32
> = 200	1			1
>200	0.22	0.07-0.73	0.01	0.89	0.24-3.2	0.85
HIV RNA copies/ml
> = 100000	1			1
<100000	1.2	0.3- 5.3	0.82	0.38	0.04- 3.3	0.4
WHO stages
I + II	1			1
III + IV	4.3	1.4-13.4	0.01	4.9	1.2-19.9	0.02
TB coinfection
No	1			1
Yes	1.4	0.4-1.8	0.5	0.23	0.03-1.9	0.17

OR Odds ratio, 95% CI 95% confidence Interval; n = total number of participants who have CD4+ count and plasma HIV RNA measurement at 6 month of HAART.

ISSN: 1742-6405